Investors
Invest in InDex
Pharmaceuticals
InDex Pharmaceuticals Holding AB (publ) published its interim report Q1 for January-March 2021 on May 5, 2021 at 08:00 a.m. CEST.
-
Interim report Q2 2021
-
CEO Peter Zerhouni presents at Pareto Securities’ Healthcare Conference 2021
-
Interim report Q3 2021
InDex Pharmaceuticals in numbers
-
15-30
The most common age of an ulcerative colitis diagnosis
-
2 Million
Patients living with ulcerative colitis in the US and Europe
-
6.3 billion USD
Total yearly sales of medications for ulcerative colitis
-
8 billion USD
The estimated total yearly sales of medication for ulcerative colitis in 2023
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis.
Investor contact
